Stablepoint Partners LLC Sells 7,549 Shares of CVS Health Corporation $CVS

Stablepoint Partners LLC decreased its holdings in CVS Health Corporation (NYSE:CVS) by 7.6% during the 3rd quarter, Holdings Channel.com reports. The fund owned 91,861 shares of the pharmacy operator’s stock after selling 7,549 shares during the quarter. CVS Health accounts for 1.1% of Stablepoint Partners LLC’s investment portfolio, making the stock its 22nd biggest holding. Stablepoint Partners LLC’s holdings in CVS Health were worth $6,925,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. SOA Wealth Advisors LLC. increased its holdings in CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after acquiring an additional 131 shares during the last quarter. Symmetry Partners LLC grew its position in shares of CVS Health by 2.5% during the 3rd quarter. Symmetry Partners LLC now owns 5,826 shares of the pharmacy operator’s stock valued at $439,000 after purchasing an additional 141 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in CVS Health by 72.1% during the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 142 shares in the last quarter. HF Advisory Group LLC increased its position in shares of CVS Health by 2.9% in the third quarter. HF Advisory Group LLC now owns 5,219 shares of the pharmacy operator’s stock worth $393,000 after purchasing an additional 145 shares during the last quarter. Finally, United Asset Strategies Inc. increased its holdings in shares of CVS Health by 1.8% in the 3rd quarter. United Asset Strategies Inc. now owns 8,852 shares of the pharmacy operator’s stock worth $667,000 after buying an additional 154 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Neutral Sentiment: Analyst coverage and stock-forecast pages are drawing attention but contain mixed signals rather than a clear catalyst; investors are watching updates to models and consensus estimates. CVS Health Corporation (CVS) Stock Forecasts
• Neutral Sentiment: Media coverage and analyst write-ups note CVS as a trending name — highlighting investor interest but not providing a definitive directional driver by itself. CVS Health Corporation (CVS) Is a Trending Stock
• Negative Sentiment: The Trump administration proposed keeping Medicare Advantage payment rates roughly flat next year (around a 0.09% average increase), which directly pressures revenue and margin expectations for insurers and plan sponsors — including CVS’s Medicare business (Aetna). That proposal triggered steep sell-offs in major health insurers and was cited as the main reason for sharp share weakness in after-hours trading. Trump Administration proposes keeping steady Medicare rates paid to insurers, WSJ reports Health insurers tumble after Trump administration proposes keeping Medicare Advantage rates flat next year Humana, UnitedHealth, and CVS Stocks Plunge After Medicare Rates Blow
• Negative Sentiment: Congressional investigators allege CVS used contracting and platform tactics to shut out competing pharmacy hubs, drawing House Judiciary attention and adding antitrust/regulatory risk. That kind of regulatory scrutiny can lead to fines, remedies, or business restrictions that would pressure longer-term growth and valuations. CVS accused of shutting out rival pharmacy hubs in House Judiciary investigation House report alleges CVS aimed to stifle pharmacy hub competition
• Neutral Sentiment: Local and trade coverage highlights CVS’s ongoing fights with regulators (FTC, Congress) while it positions itself as a partner in healthcare reform — a reminder that strategy and legal/regulatory noise will remain part of the stock’s narrative. Woonsocket-based CVS battles Congress, FTC and courts while positioning itself as healthcare reform partner

CVS Health Stock Performance

NYSE:CVS opened at $83.97 on Tuesday. CVS Health Corporation has a 52-week low of $53.36 and a 52-week high of $85.15. The firm has a market capitalization of $106.59 billion, a PE ratio of 220.98, a P/E/G ratio of 0.76 and a beta of 0.48. The stock has a 50-day simple moving average of $79.17 and a two-hundred day simple moving average of $74.97. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.63 and a current ratio of 0.83.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. The business had revenue of $102.87 billion during the quarter, compared to analyst estimates of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The company’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Analysts forecast that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Thursday, January 22nd will be given a dividend of $0.665 per share. The ex-dividend date is Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.2%. CVS Health’s dividend payout ratio is currently 700.00%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on CVS shares. Robert W. Baird increased their price target on shares of CVS Health from $82.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Wolfe Research raised their target price on shares of CVS Health from $85.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Mizuho boosted their target price on shares of CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. UBS Group restated an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of CVS Health in a report on Thursday, December 4th. Nineteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $94.86.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.